RNXT
RenovoRx Inc
NASDAQ: RNXT · HEALTHCARE · BIOTECHNOLOGY
$0.85
+7.71% today
Updated 2026-06-04
Market cap
$38.40M
P/E ratio
—
P/S ratio
25.79x
EPS (TTM)
$-0.33
Dividend yield
—
52W range
$1 – $1
Volume
0.4M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
6.3
Growth
B7.3
Quality
B+2.5
Profitability
F5.0
Valuation
C+2/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$7.03
+727.06%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 185.80% QoQ
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-3.77M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $43000.00 | $1.12M | $1.49M |
| Net income | $-9.77M | $-10.23M | $-8.81M | $-11.17M | $-3.52M |
| EPS | — | — | — | — | $-0.33 |
| Free cash flow | $-8.81M | $-10.26M | $-9.14M | $-10.97M | $-3.77M |
| Profit margin | — | — | -20,497.67% | -994.48% | — |
Peer comparison
Smart narrative
RenovoRx Inc trades at $0.85. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. TTM revenue stands at $1.49M.
Frequently asked questions
What is RenovoRx Inc's stock price?
RenovoRx Inc (RNXT) trades at $0.85, on a P/S of 25.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is RenovoRx Inc overvalued?
RenovoRx Inc carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of RenovoRx Inc (RNXT)?
The 12-month analyst consensus target is $7.03, about 727.1% above the current $0.85. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is RenovoRx Inc's revenue?
RenovoRx Inc's trailing twelve-month revenue is $1.49M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio25.79x
ROE-100.50%
Beta1.00
50D MA$0.91
200D MA$0.99
Shares out0.05B
Float0.04B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—